Holen Sie sich die Stockscreener-App
9.45
15.53%
1.27
Handel nachbörslich:
9.34
-0.11
-1.16%
Schlusskurs vom Vortag:
$8.18
Offen:
$8.07
24-Stunden-Volumen:
520.27K
Relative Volume:
0.68
Marktkapitalisierung:
$50.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.92M
KGV:
-18.53
EPS:
-0.51
Netto-Cashflow:
$-18.92M
1W Leistung:
+15.24%
1M Leistung:
+298.73%
6M Leistung:
-19.02%
1J Leistung:
-73.08%
1-Tages-Spanne:
$7.75
$9.50
1-Wochen-Bereich:
$7.02
$10.40
52-Wochen-Spanne:
$1.98
$39.30
Cel-Sci Corp. Stock (CVM) Company Profile
Firmenname
Cel-Sci Corp.
Sektor
Branche
Telefon
703-506-9460
Adresse
8229 Boone Boulevard, Suite 802, Vienna, VA
Vergleichen Sie CVM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
9.45 | 42.00M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-02 | Eingeleitet | Dawson James | Buy |
Cel-Sci Corp. Aktie (CVM) Neueste Nachrichten
What moving averages say about CEL SCI CorporationDaily Market Momentum Summary and Strategy - Newser
What makes CEL SCI Corporation stock price move sharply7-Day Equity Return Range Forecast Model - Newser
Is CEL SCI Corporation stock poised for growthPredictable Return Plan with Entry Guidance - Newser
Is CEL SCI Corporation stock entering bullish territoryTechnical Confirmation System with Signal Alerts - Newser
SRCE names Andrea G. Short CEO; founder shifts to Executive Chairman | CVM SEC FilingForm 4 - Stock Titan
How did CVM's operating expenses trend in Q1 2025? - AInvest
CEL-SCI Corp Insider Buying: CEO Geert Kersten Acquires Additional Shares - AInvest
Trading Halted for CVM Amidst Volatility Pause - AInvest
CEL-SCI Corporation Stock (CVM) Opinions on $5.7 Million Offering Announcement - Quiver Quantitative
Cel-Sci Corp (CVM) Stock: A Year of Declines and Increases - investchronicle.com
Price momentum metrics for CEL SCI Corporation explainedTechnical Entry Plan with Risk Minimization - Newser
Is CEL SCI Corporation stock poised for growth Free Daily Growth Stock Pick Reports - Newser
Should I hold or sell CEL SCI Corporation stock in 2025Unlock exclusive stock market forecasts - jammulinksnews.com
Does CEL SCI Corporation stock perform well during market downturnsBuild wealth with long-term growth strategies - jammulinksnews.com
What is the risk reward ratio of investing in CEL SCI Corporation stockMaximize your gains with expert trading tips - jammulinksnews.com
How strong is CEL SCI Corporation company’s balance sheetCapitalize on market momentum for maximum gains - jammulinksnews.com
What institutional investors are buying CEL SCI Corporation stockAchieve consistent profits with disciplined trading - jammulinksnews.com
What analysts say about CEL SCI Corporation stockConsistent double returns - PrintWeekIndia
Is CEL SCI Corporation a good long term investmentUnrivaled growth potential - jammulinksnews.com
CEL SCI Corporation Stock Analysis and ForecastFree Stock Selection - jammulinksnews.com
What drives CEL SCI Corporation stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
Is CEL SCI Corporation stock a growth or value playBreakout Setup Scanner - Newser
CVM’s Market Whiplash: -89.97% YTD Decline, 71.11% Rise in 30 Days - investchronicle.com
How CEL SCI Corporation stock performs during market volatilityRapid Gain Targets - Newser
Why CEL SCI Corporation stock attracts strong analyst attentionLow Risk Trade Timing Signals - Newser
NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison - Defense World
CEL-SCI Closes $5.7 Million Stock Offering - MarketScreener
CEL-SCI raises $5.7 million in at-market offering of common stock - Investing.com
CEL-SCI Secures $5.7M Funding Boost: What This Means for Their Cancer Immunotherapy Pipeline - Stock Titan
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
CEL-SCI's $5.7M Stock Offering: A Lifeline for Multikine or a Signal of Strained Viability? - AInvest
Cel-Sci announces pricing of $5.7 million offering - MarketScreener
CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled - NewsBreak: Local News & Alerts
CEL-SCI prices $5.7 million common stock offering at $3.82 per share By Investing.com - Investing.com South Africa
CEL-SCI prices $5.7 million common stock offering at $3.82 per share - Investing.com
Cel-Sci Corp (AMEX: CVM) – Does It Provide Stability And Growth? - Stocksregister
CEL-SCI partners with Saudi pharmaceutical firm to bring Multikine to market By Investing.com - Investing.com South Africa
CEL-SCI stock soars after Saudi partnership for cancer drug Multikine - Investing.com Canada
CEL-SCI partners with Saudi pharmaceutical firm to bring Multikine to market - Investing.com Canada
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer - Yahoo Finance
3 AI-Driven Medical Device Stocks to Watch in 2025 - The Globe and Mail
DeFi Dev Corp. and Switchboard Join Forces to Advance RWA Oracle Infrastructure on Solana - The Globe and Mail
CEL-SCI applauds FDA approval of Merck’s Keytruda for head and neck cancer - Investing.com Canada
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients - Yahoo Finance
Two Sigma Investments LP Sells 28,248 Shares of CEL-SCI Co. (NYSE:CVM) - Defense World
CVM stock touches 52-week low at $2.32 amid sharp annual decline By Investing.com - Investing.com South Africa
Finanzdaten der Cel-Sci Corp.-Aktie (CVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):